U.S. markets close in 1 hour 4 minutes

Wave Life Sciences Ltd. (WVE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.35+0.11 (+1.52%)
As of 2:53PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close7.24
Open7.31
Bid7.30 x 900
Ask7.32 x 800
Day's Range7.25 - 7.46
52 Week Range4.82 - 19.98
Volume234,801
Avg. Volume978,365
Market Cap366.452M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-3.38
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study
    Benzinga

    Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study

    Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin deficiency (AATD). AATD is a genetic disorder that may result in lung disease or liver disease. Up to 40% editing of human SERPINA1 Z-allele mRNA in the liver was observed at a single time point, which resulted in a therapeutically meaningful increase in circulating functional wild-type AAT protein. Ed

  • Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
    GlobeNewswire

    Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

    First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating functional AAT protein Wave’s program in alpha-1 antitrypsin deficiency aims to correct the single base mutation in mRNA derived from the SERPINA1 Z allele, thereby addressing both lung and liver manifestations of the disease CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Na

  • Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

    CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. Dr. Bolno will provide a corporate update and discuss Wave’s pipeline programs, including the first in vivo data from the company’s ADAR editing discovery program for alpha-1 antitrypsin deficiency (AATD). A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci. Investor Contact:Kate Rausch617-949-4827krausch@wavelifesci.com Media Contact:Alicia Suter617-949-4817asuter@wavelifesci.com